4.7 Article

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy

期刊

CANCER LETTERS
卷 371, 期 1, 页码 117-124

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.10.040

关键词

Chemoresistance; Multiple myeloma; Myeloid-derived suppressor cells; Neutrophils

类别

资金

  1. Multiple Myeloma Research Foundation
  2. NIH grant [T32CA009171]
  3. Cancer Center Support Grant [CA010815, P30-CA76292]

向作者/读者索取更多资源

Multiple myeloma (MM) is an incurable cancer of plasma cells localized preferentially in the bone marrow (BM). Resistance to chemotherapy represents one of the main challenges in MM management. BM microenvironment is known to play a critical role in protection of MM cells from chemotherapeutics; however, mechanisms responsible for this effect are largely unknown. Development of MM is associated with accumulation of myeloid-derived suppressor cells (MDSCs) mostly represented by pathologically activated relatively immature polymorphonuclear neutrophils (PMN-MDSCs). Here, we investigated whether PMN-MDSCs are responsible for BM microenvironment-mediated MM chemoresistance. Using in vivo mouse models allowing manipulation of myeloid cell number, we demonstrated a critical role for myeloid cells in MM growth and chemoresistance. PMN-MDSCs isolated from MM-bearing host are immunosuppressive and thus, functionally distinct from their counterpart in tumor-free host neutrophils. We found, however, that both PMN-MDSCs and neutrophils equally promote MM survival from doxorubicin and melphalan and that this effect is mediated by soluble factors rather than direct cell-cell contact. Our data indicate that targeting PMN-MDSCs would enhance chemotherapy efficacy in MM. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medical Laboratory Technology

Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking

Hui Chen, Zhao Li, Sheng Feng, Melissa Richard-Greenblatt, Emily Hutson, Stefen Andrianus, Laurel J. Glaser, Kyle G. Rodino, Jianing Qian, Dinesh Jayaraman, Ronald G. Collman, Abigail Glascock, Frederic D. Bushman, Jae Seung Lee, Sara Cherry, Alejandra Fausto, Susan R. Weiss, Hyun Koo, Patricia M. Corby, Alfonso Oceguera, Una O'Doherty, Alfred L. Garfall, Dan T. Vogl, Edward A. Stadtmauer, Ping Wang

Summary: The study developed a high-sensitivity SARS-CoV-2 antigen detection assay to track antigen burden in respiratory samples from different populations. Results showed that the assay accurately detects acute infections, with different outcomes observed in immunocompetent and immunocompromised patients, making it useful for screening and monitoring patients' antigen burden.

CLINICAL CHEMISTRY (2022)

Letter Oncology

Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy

Alfred Garfall, Adam Cohen, Edward Stadtmauer, Sandra Susanibar-Adaniya, Dan Vogl, Adam Waxman

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, Beth Blackwell, Paul K. Wallace, Surendra Dasari, Dan T. Vogl, Yvonne Efebera, Mingwei Fei, Nancy Geller, Sergio Giralt, Theresa Hahn, Alan Howard, Mindy Kohlhagen, Heather Landau, Parameswaran Hari, Marcelo C. Pasquini, Muzaffar H. Qazilbash, Philip McCarthy, Nina Shah, David H. Vesole, Edward Stadtmauer, David Murray

Summary: Measuring response is crucial for multiple myeloma patients, and Mass-Fix and MRD have been identified as effective indicators for predicting survival outcomes.

BLOOD CANCER JOURNAL (2022)

Article Oncology

A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

Hui Deng, Cindy Lin, Laura Garcia-Gerique, Shuyu Fu, Zachary Cruz, Erin E. Bonner, Matthew Rosenwasser, Sridharan Rajagopal, M. Naveen Sadhu, Chandru Gajendran, Mohd Zainuddin, Ramachandraiah Gosu, Dhanalakshmi Sivanandhan, Miriam A. Shelef, Brian Nam, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova

Summary: PAD4 plays a critical role in neutrophil migration in cancer, and targeting PAD4 with a small molecule inhibitor can suppress tumor growth and metastasis and enhance the efficacy of immune checkpoint blockade therapy.

CANCER RESEARCH (2022)

Meeting Abstract Hematology

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Brian Hoeynck, Wei-Ting Hwang, Alfred L. Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Adam D. Cohen

Meeting Abstract Hematology

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Adam D. Cohen, Alfred L. Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Oksana De Mesa, Elizabeth Kane, Charles Nichols, Beatrice Razzo, Edward A. Stadtmauer

Article Oncology

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Mark A. Dawson, Gautam Borthakur, Brian J. P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria -Victoria Mateos, Natalia Tovar, Paul Yeh, Regina Garcia Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson

Summary: Molibresib, a selective inhibitor of BET proteins, was evaluated as a monotherapy for hematological malignancies. The study consisted of dose escalation to determine the recommended dose and dose expansion to assess safety and efficacy in relapsed/refractory MDS and CTCL patients. Results showed limited antitumor activity and significant toxicities, suggesting the need for combination regimens with molibresib.

CLINICAL CANCER RESEARCH (2023)

Article Hematology

Progressive multifocal leukoencephalopathy in multiple myeloma

Brian W. Hoeynck, Adam D. Cohen, Edward A. Stadtmauer, Sandra P. Susanibar-Adaniya, Dan T. Vogl, Adam J. Waxman, Mark Bardsley, Samantha Le, Lexis LaMaestra, Alfred L. Garfall

Summary: Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal disease that affects the central nervous system. It is caused by the reactivation of the JC virus in individuals with weakened immune systems such as those with HIV, cancer, or taking immunosuppressive medications. PML has been rarely reported in multiple myeloma patients, and this study describes six cases of PML among multiple myeloma patients treated at a specific institution between 2013 and 2022, including two cases associated with recently developed BCMA-directed immunotherapies.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Article Genetics & Heredity

Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas

Ernest J. J. Nelson, Maria A. A. Gubbiotti, Alicia M. M. Carlin, MacLean P. P. Nasrallah, Vivianna M. M. Van Deerlin, Sarah E. E. Herlihy

Summary: This study evaluated the addition of a rapid real-time PCR assay to the testing algorithm for determining the IDH mutational status in glioma patients. The results showed that the RT-PCR assay had 100% concordance with immunohistochemistry and sequencing studies, and had a faster turnaround time compared to sequencing studies (average 2.6 days). Therefore, this RT-PCR assay can be reliably implemented for determining the IDH mutation status in glioma patients.

MOLECULAR DIAGNOSIS & THERAPY (2023)

Letter Oncology

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma

Xinhe Shan, Qi Long, Alfred L. Garfall, Sandra P. Susanibar-Adaniya

BLOOD CANCER JOURNAL (2023)

Article Oncology

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei-Ting Hwang, Dan T. Vogl, Adam J. Waxman, Simon F. Lacey, Vanessa E. Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer

Summary: This study conducted a clinical trial of CAR T cells in multiple myeloma patients and found that it can be a safe and effective treatment for the disease. The results demonstrate the relationship between early treatment and CAR T cell reexpansion and durable clinical response.

BLOOD CANCER DISCOVERY (2023)

Article Oncology

Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma

Kavita M. Dhodapkar, Adam D. Cohen, Akhilesh Kaushal, Alfred L. Garfall, Renee Julia Manalo, Allison R. Carr, Samuel S. McCachren III, Edward A. Stadtmauer, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Michael C. Milone, Madhav Dhodapkar

Summary: This study combined multiple approaches to study the tumor/immune cells in the tumor microenvironment of myeloma patients before and after BCMA CAR T therapy. The findings suggest that lower diversity of T-cell receptor repertoire, presence of hyperexpanded clones and exhausted phenotype, as well as the presence of specific cells in the bone marrow are associated with shorter progression-free survival following therapy. Conversely, longer progression-free survival is associated with an increased proportion of certain cells and the emergence of cells expressing marrow-residence genes. Tumor recurrence is associated with the emergence of new dominant clones.

BLOOD CANCER DISCOVERY (2022)

Review Oncology

Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy

Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu

Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.

CANCER LETTERS (2024)

Article Oncology

HMGB1 in the interplay between autophagy and apoptosis in cancer

Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang

Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.

CANCER LETTERS (2024)

Article Oncology

Epigenetic inhibition of CTCF by HN1 promotes dedifferentiation and stemness of anaplastic thyroid cancer

Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge

Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.

CANCER LETTERS (2024)

Article Oncology

Autophagy machinery in glioblastoma: The prospect of cell death crosstalk and drug resistance with bioinformatics analysis

Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi

Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.

CANCER LETTERS (2024)

Article Oncology

Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase

Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang

Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.

CANCER LETTERS (2024)